Anxiety disorders in Adults:
- Generalized anxiety disorder, neurasthenia, adjustment disorder;
- In patients with various somatic (asthma, irritable bowel syndrome, SLE, coronary heart disease, hypertension, arrhythmias), dermatological, oncological and other diseases;
- Sleep disorders associated with anxiety;
- Premenstrual stress syndrome;
- Alcohol withdrawal syndrome;
- To ease withdrawal symptoms when quitting smoking.
morfolinoetiltioetoksibenzimidazol dihydrochloride 10 mg
Excipients: potato starch, microcrystalline cellulose, lactose, povidone, magnesium stearate.
Afobazol® - a derivative of 2-mercaptobenzimidazole, selective anxiolytic, not belonging to the class of benzodiazepine receptor agonists. It prevents the development of membranozavisimyh changes in GABA-receptor.
The drug has anxiolytic effects with an activating component, are not accompanied by gipnosedativny effects (sedation detected at doses 40-50 times higher than the ED50 for the anxiolytic effect). There are no muscle relaxant properties of the drug, a negative impact on memory and attention. In applying the drug is not formed drug dependence and withdrawal symptoms do not develop.
The drugs are sold mainly in the form of a combination of anxiolytic (antianxiety) and easily stimulating (activating) effects. Reducing or eliminating anxiety (concern, foreboding, fear, irritability), strength (fearfulness, tearfulness, anxiety, inability to relax, insomnia, fear), and, therefore, somatic (muscular, sensory, cardiovascular, respiratory, gastrointestinal intestinal symptoms), autonomic (dry mouth, sweating, dizziness), cognitive (difficulty concentrating, impaired memory) violations observed at 5-7 days of treatment afobazole. The maximum effect is achieved by the end of 4 weeks of treatment and stored in posleterapevticheskom average period of 1-2 weeks.
Especially shows the use of the drug in patients with predominantly asthenic personality traits as alarming suspiciousness, insecurity, increased vulnerability and emotional lability, tendency to emotional and stress reactions. Afobazol® toxic (LD50 in rats is 1.1 g at ED50 1 mg).
Cmax of 0.13 ± 0.073 mg / ml.
The average retention time of the drug in the body -. 1.6 ± 0.86 hours intensively distributed by a well-vascularized organs.
T1 / 2 of 0.82 hours.
Perhaps: allergic reactions, increased individual sensitivity
- Lactation (breastfeeding);
- The age of 18;
- Hypersensitivity to the drug.
Novo-Passit 200 ml solution $29.70
Novo-Passit 100 ml solution $18.70